These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28552466)

  • 1. Methylnicotinate stimulated prostaglandin synthesis in patients with schizophrenia: A preliminary investigation.
    Ross BM
    Prostaglandins Leukot Essent Fatty Acids; 2018 Sep; 136():99-102. PubMed ID: 28552466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.
    Morrow JD; Awad JA; Oates JA; Roberts LJ
    J Invest Dermatol; 1992 May; 98(5):812-5. PubMed ID: 1373750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.
    Messamore E; Hoffman WF; Janowsky A
    Schizophr Res; 2003 Aug; 62(3):251-8. PubMed ID: 12837522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis.
    Maclean R; Ward PE; Glen I; Roberts SJ; Ross BM
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):927-33. PubMed ID: 14499309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans following the application of sorbic acid.
    Morrow JD; Minton TA; Awad JA; Roberts LJ
    Arch Dermatol; 1994 Nov; 130(11):1408-12. PubMed ID: 7979442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry.
    Ross BM; Hughes B; Turenne S; Seeman M; Warsh JJ
    Eur Neuropsychopharmacol; 2004 May; 14(3):191-7. PubMed ID: 15056478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.
    Smesny S; Rosburg T; Riemann S; Baur K; Rudolph N; Berger G; Sauer H
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jun; 72(6):393-402. PubMed ID: 15885994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde.
    VanderEnde DS; Morrow JD
    J Am Acad Dermatol; 2001 Jul; 45(1):62-7. PubMed ID: 11423836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.
    Smesny S; Rosburg T; Baur K; Rudolph N; Sauer H
    Neuropsychopharmacology; 2007 Oct; 32(10):2067-73. PubMed ID: 17314920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical benzoic acid induces the increased biosynthesis of prostaglandin D2 in human skin in vivo.
    Downard CD; Roberts LJ; Morrow JD
    Clin Pharmacol Ther; 1995 Apr; 57(4):441-5. PubMed ID: 7712673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin sensitivity and the arachidonic acid pathway in schizophrenia.
    Messamore E; Hoffman WF; Yao JK
    Schizophr Res; 2010 Sep; 122(1-3):248-56. PubMed ID: 20417059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder.
    Ross BM; Ward P; Glen I
    J Affect Disord; 2004 Oct; 82(2):285-90. PubMed ID: 15488259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia.
    Messamore E
    Prostaglandins Leukot Essent Fatty Acids; 2003 Dec; 69(6):413-9. PubMed ID: 14623495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia.
    Smesny S; Klemm S; Stockebrand M; Grunwald S; Gerhard UJ; Rosburg T; Sauer H; Blanz B
    Prostaglandins Leukot Essent Fatty Acids; 2007 Aug; 77(2):79-85. PubMed ID: 17904833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin skin flush in schizophrenia: a preliminary report.
    Ward PE; Sutherland J; Glen EM; Glen AI
    Schizophr Res; 1998 Feb; 29(3):269-74. PubMed ID: 9516668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model.
    Papaliodis D; Boucher W; Kempuraj D; Michaelian M; Wolfberg A; House M; Theoharides TC
    J Pharmacol Exp Ther; 2008 Dec; 327(3):665-72. PubMed ID: 18784348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia: a biochemical disorder?
    Horrobin DF
    Biomedicine; 1980 May; 32(2):54-5. PubMed ID: 7388116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin subsensitivity is associated with functional impairment in schizophrenia.
    Messamore E
    Schizophr Res; 2012 May; 137(1-3):180-4. PubMed ID: 22445461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia.
    Yao JK; Dougherty GG; Gautier CH; Haas GL; Condray R; Kasckow JW; Kisslinger BL; Gurklis JA; Messamore E
    Schizophr Bull; 2016 Mar; 42(2):369-76. PubMed ID: 26371338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of neonatal treatment with the TRPV1 agonist, capsaicin, on adult rat brain and behaviour.
    Newson PN; van den Buuse M; Martin S; Lynch-Frame A; Chahl LA
    Behav Brain Res; 2014 Oct; 272():55-65. PubMed ID: 24975423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.